Index

'863' Program (National High-Tech Development Program) 22, 32, 40, 41, 159

'973' Program (National Basic Research Program) 32, 40, 41

1035 Project (Medical and Pharmaceutical Innovation)

abuse, prevention of 142-3
administrative enforcement of patent rights 141-2
agri-biotechnology inventions/patents 59-60, 88-9
agricultural products 39-40
Amgen 172
Amgen Inc. v. Chugai Pharmaceutical Co. 101, 124
animal biotechnology 40, 99, 101-5
see also transgenic animals and plants
anti-commons tragedy 12-13, 140-41, 176, 177
Antitrust Law (Anti-Monopoly Law) 63-5, 167, 172, 177
AstraZeneca 43-4

'back door' patenting 103-5, 165, 177
Bayh-Dole Act (United States)/Bayh-Dole style of ownership 138, 140, 168, 169, 177
Beijing Academy of Military Science 90
Beijing BioBridge Science 45, 58, 76
Beijing Genomics Institute 32
Beijing Medical Academy: Pharmaceutical Institute 58
Beijing Shuanghe Pharmaceutical Co. 145
Beijing Sinovac Biotechnology 45, 58, 76
Beijing Starvax International 45
Beijing University Faculty of Medicine 75
Beijing Wantai Biological Pharmacy Enterprise 58, 76
beverages 163, 165
biodiversity 105-6
Biodiversity Convention 167
Biogen Inc./Human-beta interferon 126
Biogen/Alpha-Interferon II 126
biological materials 99
biopharmaceuticals 34-5
Biotechnology Development Center 41
Biotechnology Institute of China: Academy of Agriculture Science 121-2
bird flu 76
Bolar exception ('safe harbor') 146, 148-9, 168
Boston Children's Hospital 57
Brazil 40, 150
Bristol-Myers Squibb Co. v. Rhone-Poulenc Rorer 146
Bt cotton 59-60
Calgene 171
Canada 151
Program on Genomics and Global Health 10
capacity and infrastructure 30-48
foreign investment and international collaboration 43-5
see also R&D
CapitalBio 76, 174
case studies 69–94
agri-biotechnology patent infringement case 88–9
Chinese drug companies v. GSK 86
Ganli v. Eli Lilly and Eli Lilly v. other Chinese companies 84–6
‘Glowing Fungus’ case 82–3
‘H101’ Case 83
impact of patents on innovation 89–91
Sankyo v. Beijing Wansheng 86–8
traditional Chinese medicines patent infringement case 88
‘Viagra’ Case (Chinese Drug Companies v. Pfizer) 83–4
see also filing and granting of patents
chemical compounds, new 175
chemical drugs 30, 74, 75
chemical entity, new 54, 55
chemical substances 82, 99, 165
China Pharmaceutical University v. Pfizer 87–8
choice of patent regime for innovation 164–8
cloning 81
animal 33
human 36–8, 112–15, 175
combining comparison principle 130
commercialization 59–65, 168
agri-biotechnology inventions 59–60
licensing, technology transfers and antitrust issues 63–5
pharmaceutical inventions 60–61
trends, analysis of 61–3
Commission on Intellectual Property Rights report 15–16
compulsory licensing 149–51, 167, 169, 170
Conor Medsystems Inc. v Angiotech Pharmaceutical Inc. 127–8
counterfeits 177
cumulative innovation model 12
damages for infringement 143–4
data exclusivity 146–9, 175
design patents 70, 163
development and market scale of pharmaceuticals 25–7
Diamond v. Chakrabarty 101, 111–12
diseases, common 25
DNA fragments 100–101
domestic applicants 163, 166, 167, 175
filing and granting of patents 70, 72, 73, 74, 81
Drug Administration Law 111, 148
drug discovery 33
drug registration and patent, linkage of 144–6
effective results 131–3
Eisai (Japan) 124
encouraging before catching strategy 143
Endostar 34, 40, 55, 56–7, 60, 63
EntreMed 55
Europe 10, 126–8
European Chemical Industry Council 153
European Community Biotechnology Directives 97, 98, 100
European Community v. Canada 149
European Patent Convention 98
European Patent Office 71, 86, 126
Board of Appeals 126
Opposition Division 100, 126
European Union 37, 39, 96, 98–9, 101, 105
evergreen patents 169
Examination Guidelines (SIPO’s Guidelines for Examination 2006) 31, 81, 97–8, 99, 100, 120, 166
animal and plant varieties 102–4
genes, DNA fragments and proteins 100–101
medical and pharmaceutical products 106–7
microorganisms 112
non-obviousness or inventiveness 128, 130–31
stem cells and human cloning 113–15
utility or practical applicability 133
exceptions to patent rights 146–53
compulsory licensing 149–51
market approval exemption and data exclusivity 146–9
parallel imports 151–3
exhaustion doctrine 151
experimental exemption 170
exploitation 63

failure to work 150
'feeding fishes in the pond' strategy 143
filing and granting of patents 69–81
gene-related inventions 73–4
general trend 69–73
pharmaceuticals 74–7
stem cells and cloning, patent applications for 81
traditional Chinese medicines 77–81
Five Year Plan (2006–2010) 38
foods 163, 165
foreign applicants for patents 89, 163, 166, 167, 175
filing and granting of patents 70, 72, 73, 74, 77, 79, 81
foreign investment in capacity and infrastructure 43–5
France 78
Intellectual Property Code 100
Fudan University 36
funding 40–41, 62, 80, 159, 161, 163, 177

Ganli v. Eli Lilly and Eli Lilly v. other Chinese companies 84–6, 147–8
Gendicine 34, 40, 63
gene sequences 76
gene therapy products 34, 40, 55–6
gene-related inventions 73–4
generic products 52–3
genes 100–101
Genetech/Expression in Yeast 126
genetic materials 99
genetic resources 105–6
genetically modified plants 32–3, 59–60
genomics as basic research 30–33
Germany 5, 60, 62, 71, 72, 78, 159
Glaxo v. Southwestern Pharmaceutical 147
GlaxoSmithKline 27, 43, 86
'Glowing Fungus' case 82–3
'Gold Rice' case 170–71

Index

Good Laboratory Practice centers 41
Good Laboratory Practice key laboratories 41
Good Manufacturing Practice 25–6
government see R&D, government's role in
grant back condition 64–5
granting of patents see filing and granting of patents
Guangzhou Bio-medicine and Health Institute 149
Guangzhou Welman Pharmaceutical Co. 145
'Guidelines for the Healthcare Industry' 38–9

H101 (Oncorine) 34, 55, 60, 63, 83
H102 34
H103 34
HD Biosciences 76
historical development of biotechnology industry 21–3
Hodosh v. Block Drug Co. 109
Hong Kong 151
Patent Ordinance 98
Hooper Trading Co. N.V./T-cell growth factor 126
hope of success 126
Howard Florey/Relaxin 100, 126–7
Hunan Agriculture University 88–9
Huawei Electronic 71
human genome initiative (HUGO) 22–3
Human Genome Project 31, 33
Human Liver Proteome Project 23
Human Proteome Organization (HUPO) 23
HUYA Bioscience International (San Diego) 45
Hybritech Inc v. Monoclonal Antibodies Inc. 123–4
imitation 52–3, 65, 159–60, 176, 177
impact of patents on innovation 89–91
Implementing Regulations 148
Imutran Ltd 107–8
increasing revenue of hospital by excessive sales of drugs' phenomenon 171
incremental innovation 53-7, 65-6, 160
'me better' drugs 54-7
'me too' drugs 53-4
India 14-15, 139, 165
industrial applicability test 132
industry-specific theory 13
innovative drugs 52, 74
Institute of Bioengineering 90
Institute of Chinese Drugs of China Academy of Traditional Chinese Medicine 110–111
Institute of Genetics of Chinese Academy of Science 31
Integra Life Sciences v. Merck KGaA 146, 149
intellectual property union 75
international collaboration and capacity and infrastructure 43-5
International Convention for the Protection of New Varieties of Plants (UPOV) 98, 102, 105
inventions, patentable 72, 96–118, 120–35
animal and plant varieties 101–5
background and general bio-patent regime 96–8
genes, DNA fragments and proteins 100–101
medical and pharmaceutical products 106–8
microorganisms 111–12
novelty 120–23
overview 98–100
plant varieties, biodiversity and genetic resources 105–6
stem cells and human cloning 112–15
traditional Chinese medicines 108–111
utility and practical applicability 131–3
see also non-obviousness or inventiveness
inventive step 126
see also non-obviousness
inventiveness 78, 80, 128–31, 163, 166, 167–8
lack of 89–90
see also non-obviousness or inventiveness
Japan 5, 10, 26, 96, 101, 164
disputes over patents 87
Examination Guidelines for Patent and Utility Model (1993) 100
filing and granting of patents 72, 78, 81
Patent Office 71
R&D 54
technological capacity 159
Jiangsu Haosen Pharmaceutical Co. 85–6
Jiangxi Green Enterprise 78
JieMing Biopharmaceutical Institute 83
joint ventures 63, 159
'junk patents' 110, 163, 164, 166
KSR Int'l Co. v Teleflex Inc. 125
Kunming Drug Company 111
Law on Legislation 139–40
licensing 63–5
litigations 90, 143
local working requirement 150
Loyola University 45
market approval exemption 146–9, 169
Massachusetts University 113
'me better' drugs 54–7, 65–6
'me first' drugs 57
'me too' drugs 53–4, 57, 65–6
Measures on Administration of Pharmaceutical Registration (2002) 145
Medgenn 55, 56–7
see also Endostar
Medical and Pharmaceutical Innovation Project see 1035
Project
'Medical Science and Technology Policy' 25, 39
medicine composition 163
medicine preparation craft 163
<table>
<thead>
<tr>
<th>Index</th>
<th>185</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merck 27</td>
<td></td>
</tr>
<tr>
<td>Merck KGaA v. Integra Lifesciences Ltd 146, 149</td>
<td></td>
</tr>
<tr>
<td>Mexico 14–15</td>
<td></td>
</tr>
<tr>
<td>Institute of Intellectual Property (IMPI) 15</td>
<td></td>
</tr>
<tr>
<td>National Genomic Medicine Institute (INMEGEN) 15</td>
<td></td>
</tr>
<tr>
<td>microorganisms 99, 111–12</td>
<td></td>
</tr>
<tr>
<td>Ministry of Health 25, 37–8, 39, 111</td>
<td></td>
</tr>
<tr>
<td>‘Ethical Guidelines on Human Embryo Stem Cell Research’ 38</td>
<td></td>
</tr>
<tr>
<td>‘National Essential Drug Policy’ 171</td>
<td></td>
</tr>
<tr>
<td>Ministry of Science and Technology 7, 22, 25, 39</td>
<td></td>
</tr>
<tr>
<td>Mologen (Berlin) 45</td>
<td></td>
</tr>
<tr>
<td>Monsanto 166</td>
<td></td>
</tr>
<tr>
<td>Monsanto/Milk Production 126</td>
<td></td>
</tr>
<tr>
<td>morality and public interests 99–100, 112, 114, 169, 177</td>
<td></td>
</tr>
<tr>
<td>multinational pharmaceutical companies 44, 106, 160, 163, 165, 177</td>
<td></td>
</tr>
<tr>
<td>commercialization 62</td>
<td></td>
</tr>
<tr>
<td>disputes over patents 82, 85, 87</td>
<td></td>
</tr>
<tr>
<td>filing and granting of patents 75</td>
<td></td>
</tr>
<tr>
<td>impact of patents on innovation 90</td>
<td></td>
</tr>
<tr>
<td>innovation capacity and infrastructure 45</td>
<td></td>
</tr>
<tr>
<td>R&amp;D 54, 58</td>
<td></td>
</tr>
<tr>
<td>rights 143, 168, 169, 170, 171, 172</td>
<td></td>
</tr>
<tr>
<td>National Agricultural Biotechnology Safety Committee (Ag Biosafety) 60</td>
<td></td>
</tr>
<tr>
<td>National Basic Research Program see ‘973’ Program</td>
<td></td>
</tr>
<tr>
<td>National Biotech Group (China) 26</td>
<td></td>
</tr>
<tr>
<td>National Center for Biotechnology Development (China) 7, 22</td>
<td></td>
</tr>
<tr>
<td>National Development and Reform Commission: China Bioindustry Development Strategies 39</td>
<td></td>
</tr>
<tr>
<td>National High Tech Development Program see ‘863’ Program</td>
<td></td>
</tr>
<tr>
<td>National Key Laboratories 41</td>
<td></td>
</tr>
<tr>
<td>national laws 2–4</td>
<td></td>
</tr>
<tr>
<td>National Natural Science Fund 41</td>
<td></td>
</tr>
<tr>
<td>national patent technology transfer and trade platform plan 64</td>
<td></td>
</tr>
<tr>
<td>National People’s Congress Standing Committee 2–3, 140, 144, 152</td>
<td></td>
</tr>
<tr>
<td>The Netherlands 11</td>
<td></td>
</tr>
<tr>
<td>New Drug Certificate 111</td>
<td></td>
</tr>
<tr>
<td>new drug selection centers 41</td>
<td></td>
</tr>
<tr>
<td>non-obviousness or inventiveness 123–31</td>
<td></td>
</tr>
<tr>
<td>China 128–31</td>
<td></td>
</tr>
<tr>
<td>Europe 126–8</td>
<td></td>
</tr>
<tr>
<td>United States 123–5</td>
<td></td>
</tr>
<tr>
<td>non-service patents 70, 78, 161</td>
<td></td>
</tr>
<tr>
<td>notable improvements/progress 128, 130–31</td>
<td></td>
</tr>
<tr>
<td>Novartis 27, 43, 44, 45, 107, 111, 149</td>
<td></td>
</tr>
<tr>
<td>novelty 130, 168</td>
<td></td>
</tr>
<tr>
<td>absolute test 121, 167–8</td>
<td></td>
</tr>
<tr>
<td>from a mixed to an absolute test 120–23</td>
<td></td>
</tr>
<tr>
<td>mixed test 121, 167–8</td>
<td></td>
</tr>
<tr>
<td>Novo Nordisk 43, 44</td>
<td></td>
</tr>
<tr>
<td>obviousness 128–9</td>
<td></td>
</tr>
<tr>
<td>Onyx Pharmaceuticals 55</td>
<td></td>
</tr>
<tr>
<td>Organon 45</td>
<td></td>
</tr>
<tr>
<td>over-the-counter products 52</td>
<td></td>
</tr>
<tr>
<td>ownership of patents for state-funded projects 138–41</td>
<td></td>
</tr>
<tr>
<td>ownership of ‘works for hire’ and joint ownership 136–7</td>
<td></td>
</tr>
<tr>
<td>parallel imports 151–3, 167, 169, 170</td>
<td></td>
</tr>
<tr>
<td>Paris Convention 102, 150</td>
<td></td>
</tr>
<tr>
<td>Patent Administration Department 151</td>
<td></td>
</tr>
<tr>
<td>Patent Administrative Authorities 141–2</td>
<td></td>
</tr>
<tr>
<td>Patent Cooperation Treaty 15, 98, 158–9, 161</td>
<td></td>
</tr>
<tr>
<td>filing and granting of patents 71, 74, 77, 80–81</td>
<td></td>
</tr>
<tr>
<td>Patent Law 5, 73, 97, 99–100</td>
<td></td>
</tr>
<tr>
<td>animal and plant varieties 102–4</td>
<td></td>
</tr>
<tr>
<td>disputes over patents 82, 84</td>
<td></td>
</tr>
<tr>
<td>genes, DNA fragments and proteins 100–101</td>
<td></td>
</tr>
<tr>
<td>medical and pharmaceutical products 107</td>
<td></td>
</tr>
</tbody>
</table>
non-obviousness or inventiveness 128, 130–31
novelty 120–23
plant varieties, biodiversity and genetic resources 106
rights 136–8, 140–42, 144, 146, 149, 150–52
stem cells and human cloning 112–14
utility or practical applicability 133
Patent Re-Examination Board disputes over patents 83–4, 85, 87, 88
non-obviousness or inventiveness 129, 130
novelty 122
Re-Examination Notification 108
stem cells and human cloning 113–14
utility or practical applicability 132
patent slave status 170
Patent Technologies in Various Industries: Present and Development Trend report 69
patent thickets 163, 169–70
persons skilled in the art 130–31, 167–8
Pfizer 27
China R&D Center 43
Lipitor 55
‘Viagra’ Case (Chinese Drug Companies v. Pfizer) 83–4
PhytoCeutica 110
‘Plan of International Technical Cooperation in Chinese Medicine’ 39
plant biotechnology 39–40
see also genetically modified plants; transgenic animals and plants
plant varieties 99, 101–6
policy 2–4
orientation 38–40
practical applicability 131–3
preparation and processes 175
prior art 121, 142–3, 167–8
non-obviousness or inventiveness 124, 125, 126, 128–9, 130, 131
problem-and-solution approach 126
production process 82
prominent substantive features 128, 130–31
prospect theory 12–13
Protection of New Varieties of Plants Regulations 1997 see Plant Variety Regulations
protection of patent rights 141–6
administrative enforcement 141–2
damages for infringement 143–4
drug registration and patent, linkage of 144–6
prevention of abuse 142–3
see also exceptions to patent rights
Protection and Technology Transfer of New Drugs Regulations (1999) 111
Protection of Varieties of Chinese Medicine Regulations (1992) 110
proteins 100–101
public interests see morality and public interests
pure innovation 65
Qing hao su (artemisine) 57, 80–81, 110–111
quantitative structure-activity relationship 56
R&D 44, 45, 52–9, 160, 162, 177
commercialization 62
imitation 52–3
incremental innovation 53–7
moving toward innovation 57–9
R&D, government’s role in 38–43
assessment 42–3
funding support 40–41
infrastructure 16, 41–2
policy orientation 38–40
R&D trends and capacities 30–38
biopharmaceuticals 34–5
drug discovery 33
genomics as basic research 30–33
stem cell research and human cloning 36–8
traditional Chinese medicines 35–6
re Bell 124–5
re Deuel 124–5
re Marek Z. Kubin and Raymond G. Goodwin 125
re O’Farrell 124–5, 126
reasonable expectation of success 126, 127, 130
Recombinant Human Thrombopoietin (rhTPO) 60–61
relevance of patents to innovation 159–64
research questions 4–7
rights 63, 64, 136–55, 177
balance of 168–72
ownership of patents for state-funded projects 138–41
ownership of ‘works for hire’ and joint ownership 136–7
see also protection of patent rights
Roche 43, 172
Fuzeon 55
role of patents 1–19, 172–5
national laws, policies and strategies 2–4
research questions 4–7
theoretical debates concerning developing countries 14–17
theoretical debates concerning industrialized countries 8–14
safe harbors 149
see also Bolar exception
Sankyo v. Beijing Wansheng 86–8, 91, 147, 148–9
Sanofi Pasteur 27
SATECM 39
scale and market of biotechnology industry 23–4
Science and Technology development 5
Science and Technology Development Plan 6
Science and Technology Progressing Law 1993 (S&T Law) 2–3, 139–40
scientific discoveries 99
screening centers 58
seed fund 177
separate comparison method 121–2, 130
service invention see works for hire
service patents 61, 70, 161
Shaanxi Chaoying Biotechnology 74
Shanghai Agriculture Research Institute 130
Shanghai Biochip Co. 43
Shanghai Fudan-Yueda Bio-Tech 76
Shanghai Genomics 45, 57–8, 75
Shanghai Genon Bio-engineering Co. 75, 103, 114
Shanghai GODE Gene Development Co. 76
Shanghai Huaguan Biochip 74
Shanghai Institute of Materia Medica 43
Shanghai Medical and Pharmaceutical Association 75
Shanghai Sunway Biotechnology 56, 75–6, 83
see also H101
Shanghai Traditional Chinese Medicines Innovation Center 110
Shanghai United Cell Biotechnology 58, 90
Shenyang Sunshine Pharmaceutical Co. (3Sbio) 60–61
Shenzhen Beike Biotechnologies 81
Shenzhen Chipscreen Biosciences 45, 76, 174
Shenzhen SiBiono GeneTech Co. 56–7, 76
see also Gendicine
shop rights 137
Sichuan Wulingshan Drug Company 111
sifuvirtide 55
Sino-United States memorandum concerning intellectual property rights 165
Sinocells Biotech 81
Yahong Li - 9781849808149
Downloaded from Elgar Online at 04/18/2019 01:40:48AM via free access
South Korea 26, 71, 72, 78, 81
SK Bio-pharmaceuticals Tech Shanghai Co. 43
State Administration of Traditional Chinese Medicine 25
State Council 63, 138
Biotech Policy 6–7
‘Outlines of National Intellectual Property Strategy’ 2
State Economic and Trade Commission 25, 39
State Food and Drug Administration 87, 145–6, 147–8
capacity and infrastructure 34, 35, 44
Guideline for Submitting Clinical Trial Applications for New Preventive Biological Products 144–5
R&D models and commercialization 55, 60
State Intellectual Property Office 150, 161, 163, 165, 166, 175
animal and plant varieties 104
disputes over patents 87
filing and granting of patents 69–70, 71, 72, 73, 76
Guidelines for Examination see Examination Guidelines
maximizing role of patents 172
medical and pharmaceutical products 107
novelty 121–2
plant varieties, biodiversity and genetic resources 106
R&D models and commercialization 63
rights 142, 152, 170
stem cells and human cloning 113–14
utility or practical applicability 133
see also Patent Re-Examination Board
State New Drug R&D Coordination and Leading Group 41
State Patent Bureau see State Intellectual Property Office
state-funded projects, ownership of patents for 138–41
Statistical Communique of Economic and Social Development 72
stem cell research 36–8, 81, 112–15, 165–6, 175, 178
strategies 2–4
sui generis system 101, 105, 110, 166
Supreme People’s Court 143–4
Explanations on Trials of New Plant Varieties Disputes (2001) 101
Switzerland 11
synthetic medicines 52
tailored incentives theory 12
Tasty Pharmaceutical Co v. Wancheng Pharmaceutical Co. 88
technological capacity 158–9
Technology Import and Export Regulations (2002) 64
technology transfers 63–5
Teva Pharmaceutical Industries 124–5
Thailand 14–15
TCELS Pharmacogenomics Project 15
Tianjin FusoGen Pharmaceuticals 55, 56, 57, 76
Tongjitang Pharmaceutical Co. 61
Torch Program 41
Trade-Related Aspects of IPRs Agreement (TRIPS) 3, 15, 163, 165, 167, 175
animal and plant varieties 101, 102–3
commercialization 64
disputes over patents 87
microorganisms 111
plant varieties, biodiversity and genetic resources 106
rights 149, 150–51, 152–3
stem cells and human cloning 112
traditional Chinese medicines 21, 25–6, 39–40, 163, 165–6, 175
commercialization 61
impact of patents on innovation 89
innovation capacity and infrastructure 30, 44–5
inventions, patentable 108–111, 122–3, 133
patent applications 77–81
Index

patent infringement case 88
R&D trends and capacities 35-6
side effect database 42
transgenic animals and plants 165, 166-7, 169, 178
triadic patents 173

UNESCO's Declaration 37
unexpected effect 129-30
Unilever 127
Union Gene Technology Group 73
United Kingdom 72, 127, 128
Commission on Intellectual Property Rights 14
United States 10, 96, 98-9, 132, 164, 166, 175, 177
annual patent filings 5
capacity and infrastructure 39
Code of Federal Regulation 140
commercialization 61, 62
disputes over patents 87
Federal, Food, Drug and Cosmetic Act 146
filing and granting of patents 72, 78, 80, 81
Food and Drug Administration 146
genes, DNA fragments and proteins 101
Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act (1984)) 146
Human Cloning Prohibition Act (2001) 37
innovation capacity and infrastructure 42, 43
National Institute of Health 37, 61, 115
non-obviousness or inventiveness 123-5
Patent Act 100, 137, 146

Patent and Trademark Office 15, 71, 100, 115, 124
plant varieties, biodiversity and genetic resources 105
R&D 57
‘Report of the President’s Commission on the Patent System 1-3’ 10
rights 145, 150, 151, 169, 172
technological capacity 159
see also Bayh-Dole Act; Bolar exception
USC 123
utility models 70, 131-3, 163-4

vaccine research 35, 39
venture capital 62, 177
Viagra 54
‘Viagra’ Case (Chinese Drug Companies v. Pfizer) 83-4

wilful silence over patent infringement 143
works for hire 61, 78, 136, 168
World Health Organization 35, 42, 111
World Intellectual Property Organization 71, 162
World Trade Organization 63, 101, 149, 150, 165, 170
Doha Declaration 150-51, 153
Worldwide Biotech & Pharmaceutical Company 44

Xiaman Amoytop Biotechnology 53
Xianling Gubao 61

Yan Huai Wei case 122
Yunnan University Technology Ltd 88-9

zhiwu invention see works for hire
Zhongguancun Bio-Pharmacy Park 41-2
Zhongxin Technology Co. 45
Imitation to Innovation in China

'This volume fills an important need for understanding about the interplay between China’s intellectual property protection system and the potential for innovation in China’s economy. Using examples from the pharmaceutical and biotech industries, the author suggests that, despite the widely documented challenges facing China’s IPR protection system, the system has a demonstrable effect on innovation. The author suggests that China’s patent system promotes innovation through economic incentives, soft factors of public encouragement, and intentional development strategies. This book is also useful as an overview of China’s biotech and pharmaceutical sectors, offering a range of richly detailed case studies on China’s industrial development strategies in these sectors. A number of important patent disputes between Chinese and foreign companies are also examined to useful effect. In the highly contentious policy world of intellectual property protection and pharmaceutical and biotech industry development, the volume offers a refreshing combination of detail and insight.'

— Pitman B. Potter, University of British Columbia, Canada

‘Yahong Li’s pioneering study, Imitation to Innovation in China, breaks new ground in closely examining the extent to which the Chinese government’s patent policies and patent activity by Chinese firms are influencing China’s coming transformation from an imitation-oriented country to an innovation-oriented one. Her combination of theoretical and empirical approaches exploring the links between public policy, patenting activity and technological innovation (commercialization) is an important contribution to development studies, not just for China but for other newly innovative countries as well.’

—William O. Hennessey, Franklin Pierce Law Center, USA

Following decades in which China’s approach to technology has been to imitate, the country is now transforming itself to become innovation-oriented. This pioneering study examines whether patents play as similar a role in promoting innovation in China as they do in the West, exploring the interplay between patents and China’s biotechnology and pharmaceutical industries in particular.

The author argues for a stronger patent regime based on an extensive review of the technological capacity, R&D models, patent filings and litigations, and issues in patent law, which involve China’s biotechnology and pharmaceutical industries. By comparing China with other developing countries and analyzing China’s uniqueness in terms of its development stage, technological capacity and the strengths and weaknesses in its patent system, the author concludes that China is distinguished from the prevailing view that patents play a limited role in innovation in developing countries. The book also discusses whether and how patents can promote innovation in China’s biotechnology and pharmaceutical industries, based on the study of market scale, R&D capacity, innovation model and patent legislation and cases.

Yahong Li is Associate Professor and Director of the LLM Program in Intellectual Property and Information Technology Law at the University of Hong Kong.